Clinical Research Directory

Inclusion Criteria: * Women ≥ 18 and ≤ 70 years of age with treatment-naïve breast cancer * Histopathologically confirmed early or locally advanced HER2-negative invasive breast cancer as defined by the ASCO/CAP guidelines while meeting the following conditions: HER2 negative: IHC 0/1 + or IHC2 + but ISH negative; Tumor stage: II-III; Primary tumor size: ≥ 1 cm Nodal Status: N0-3 * ECOG score 0 \~ 1; * Centrally confirmed BRCA1 or BRCA2 germline mutation; * At least one measurable lesion according to RECIST 1.1 * Eligible level of organ function Exclusion Criteria: * Patients with metastatic breast cancer or bilateral breast cancer; * Patients with inflammatory breast cancer; * Participated in other drug trials or received any anti-tumor therapy within 4 weeks before enrollment, including endocrine therapy, bisphosphonate therapy, immunotherapy, biological therapy or tumor embolization; * Previously received PD-1/PD-L1 antibody, CTLA-4 antibody, or other therapies against PD-1/PD-L1 inhibitors; * Previously received PARP inhibitors; * Human immunodeficiency virus (HIV) infection or known acquired immunodeficiency syndrome (AIDS); active hepatitis or combined hepatitis B and C co-infection; autoimmune hepatitis; * Confirmed history of heart failure or systolic dysfunction (LVEF \< 50%); high risk uncontrolled cardiac arrhythmias, such as atrial tachycardia; angina requiring antianginal medication * Female patients who are pregnant or lactating * History of definite neurological or psychiatric disorders, including epilepsy or dementia * Presence of interstitial lung disease, pneumonitis, or uncontrolled systemic disease (eg, diabetes mellitus, pulmonary fibrosis, acute pneumonitis, etc.)